AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 72 min read$CL

CAHILL JOHN T sold $389K of CL

CAHILL JOHN T sold 4,170 shares of COLGATE PALMOLIVE CO (CL) at $93.37 ($0.39M total) on 2026-08-06.

Original reporting
SEC EDGAR · CAHILL JOHN T
Published Aug 7, 2026, 9:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CL
Neutral
medium confidence
Mentioned
$CL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLNeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale of 4,170 shares at $93.3712 on 2026-08-06, with holdings after the sale of 28,373 shares.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no accompanying company-specific fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, liquidity needs, or scheduled personal events; without context on prior holdings or compensation, signal strength is weak.

Relevance 4/10Novelty 3/10Timing: filed after-hours on 2026-08-07, covering a sale dated 2026-08-06

Background

The article is an SEC Form 4 insider transaction disclosure for Colgate Palmolive (CL) by director John T. Cahill.

Company-level read

Ticker impact

$CLNeutralMedium confidence
Context

Colgate Palmolive director John T. Cahill sold 4,170 shares in an open-market transaction worth about $389,358 on 2026-08-06.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, but the article provides no accompanying company news, guidance, or operational/regulatory catalyst.

Market effects

Sector

No clear sector read-through from a single director sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be pre-planned or tax-related even if the filing states no 10b5-1 plan, so it may not reflect bearish fundamentals.

Key entities

  • issuer
    COLGATE PALMOLIVE CO

    Subject of the Form 4 insider sale disclosure.

  • insider
    CAHILL JOHN T

    Director who sold shares via open-market sale.

Read at source← All news

Related articles

AUG 4
$CLMed

Colgate-Palmolive Reaffirms Sales Forecast On Weak Demand

Colgate-Palmolive reaffirmed its annual net sales forecast despite a quarterly rise, citing weak North America demand. In the quarter ended June 30, net sales rose 4.9% to $5.36 billion and adjusted EPS was 99 cents. North America organic sales fell 3%, with volumes down 3.9%. The company expects 2026 adjusted earnings growth in mid-single digits and warned tariffs could offset refunds.

checkout.ie3 min
AUG 3
$CLMed

Colgate-Palmolive: Base Business EPS Increases 8% As Gross Margin Expands 140 Basis Points

Colgate-Palmolive reported Q2 2026 Base Business diluted EPS up 8% to $0.99 from $0.92, driven by 140 bps gross-margin expansion to 61.5% and higher organic sales. Reported diluted EPS fell 5% to $0.86 due to $129m pretax charges tied to its Strategic Growth and Productivity Program. Net sales rose 4.9% to $5.36b. Full-year organic outlook 1% to 4%; Base Business EPS expected mid-single-digit growth.

pulse2.com4 min
JUL 31
$CLMed

Colgate-Palmolive Q2 Earnings Call Highlights

Colgate-Palmolive (NYSE:CL) CFO Stan Sutula said Q2 material costs were slightly below expectations due to higher raw-material costs offset by tariff refunds, with no meaningful additional refunds expected. Management now expects full-year gross margin roughly flat, and warned second-half raw-material and tariff costs will be higher. It plans elevated ad spending and North America share recovery; Hill’s organic sales rose 4% excluding discontinued private-label.

yahoo.com4 min
JUL 31
$CLHighAI 9/10

Colgate-Palmolive Q2 2026 slides: strong results fuel raised guidance

Colgate-Palmolive (NYSE:CL) reported Q2 2026 results on July 31. Net sales rose 4.9% to $5.36B and organic sales grew 2.4%. Base EPS increased 8% and free cash flow rose 18% YoY to $1.5B YTD. The company raised 2026 guidance, including flat gross margin outlook and higher EPS growth, and projected $350M to $550M pre-tax charges for its 2030 program.

investing.com6 min